ReviewImmunologic research2008
DNA vaccines: developing new strategies to enhance immune responses.
Review in Immunologic research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccine.Cancer immunology, immunotherapy : CII · 2025Article
- Mosaic vaccine design targeting mutational spike protein of SAR-SCoV-2: An immunoinformatics approach.BioImpacts : BI · 2025Article
- Mechanism of Action of OralVaccines · 2024Article
- Evaluation of protective immune responses induced by DNA vaccines encodingFrontiers in veterinary science · 2024Article
- Regulatory Considerations on the Development of mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy againstFrontiers in microbiology · 2022Article
- Current view on novel vaccine technologies to combat human infectious diseases.Applied microbiology and biotechnology · 2022Review
- Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity.Journal of cellular physiology · 2021Review
- Article
- Review
- Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.Neurobiology of disease · 2020Review
- Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.Journal of molecular medicine (Berlin, Germany) · 2019Article
- A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle.International journal of molecular sciences · 2019Review
- An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.Cancer immunology, immunotherapy : CII · 2019Review
- Defensive Driving: Directing HIV-1 Vaccine-Induced Humoral Immunity to the Mucosa with Chemokine Adjuvants.Journal of immunology research · 2018Review
- Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.Frontiers in immunology · 2018Review
- Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Human vaccines & immunotherapeutics · 2017Review
- MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.Neurobiology of aging · 2017Article
- The state of gene therapy research in Africa, its significance and implications for the future.Gene therapy · 2017Review
- Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.Journal of virology · 2017Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have focused our research on understanding the basic biology of and developing novel therapeutic and prophylactic DNA vaccines. We have among others three distinct primary areas of interest which include: 1. Enhancing in vivo delivery and transfection of DNA vaccine vectors 2. Improving DNA vaccine construct immunogenicity 3. Using molecular adjuvants to modulate and skew immune responses. Key to the immunogenicity of DNA vaccines is the presentation of expressed antigen to antigen-presenting cells. To improve expression and presentation of antigen, we have investigated various immunization methods with current focus on a combination of intramuscular injection and electroporation. To improve our vaccine constructs, we also employed methods such as RNA/codon optimization and antigen consensus to enhance expression and cellular/humoral cross-reactivity, respectively. Our lab also researches the potential of various molecular adjuvants to skew Th1/Th2 responses, enhance cellular/humoral responses, and improve protection in various animal models. Through improving our understanding of basic immunology as it is related to DNA vaccine technology, our goal is to develop the technology to the point of utility for human and animal health.
Indexed as
Identifiers
19066740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.